Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1991 Nov;117(6):575–582. doi: 10.1007/BF01613291

Effects of an androgenic derivative on pre-established mammary tumours chemically induced in the rat

E Escrich 1,✉, T Ribalta 2, J Muntané 2, M C Ruiz de Villa 3, J Murillo 3, S Saez 4
PMCID: PMC12201352  PMID: 1744164

Abstract

The effects were studied of an androgenic derivative — danazol — administered at doses of 10–12 mg kg−1 day−1 during 97 days to rats with dimethylbenz[a] anthracene-induced mammary tumours. Our main observations were as follows. (a) Danazol did not influence ovarian function at the end of the assay. (b) The treatment with danazol reduced the incidence (P<0.05), number of tumours (P<0.05) and volume of malignant mammary tumours; on the other hand, the values of these parameters for benign tumours and those of doubtful expression were similar in both experimental groups. (c) Such differential action of Danazol seems to be due to the different incidence and/or content of receptors of both types of tumours. (d) The latter results lead to a hypothesis for the mechanism of action of danazol based on its behaviour at different levels.

Key words: Danazol, Breast cancer

Abbreviations

RE

oestradiol receptors

RP

progesterone receptors

References

  1. Barbieri RL, Canick JA, Makris A, Todd RB, Devies IJ, Ryan KJ (1977a) Danazol inhibits steroidogenesis. Fertil Steril 28:809–813 [PubMed] [Google Scholar]
  2. Barbieri RL, Canick JA, Ryan KJ (1977b) Danazol inhibits steroidogenesis in the rat testis in vitro. Endocrinology 101:1676–1682 [DOI] [PubMed] [Google Scholar]
  3. Barbieri RL, Lee H, Ryan KJ (1979) Danazol binding to rat androgen, glucocorticoid, progesterone, and estrogen receptors: correlation with biologic activity. Fertil Steril 31:182–186 [DOI] [PubMed] [Google Scholar]
  4. Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mama: suggestion for a new method of treatment, with illustrative cases. Lancet 2:104–107, 162–165 [PMC free article] [PubMed] [Google Scholar]
  5. Blankenstein MA, Henkelman MS, Klijn GM (1985) Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Clin Oncol 21:1493–1499 [DOI] [PubMed] [Google Scholar]
  6. Brodovsky HS, Holroyde CP, Laucius JF, Dugery C, Serbin J (1987) Danazol in the treatment of women with metastatic breast cancer. Cancer Treat Rep 71:875–876 [PubMed] [Google Scholar]
  7. Chamness GC, Asch RH, Pauerstein CJ (1980) Danazol binding and translocation of steroid receptors. Am J Obstet Gynecol 136:426–429 [DOI] [PubMed] [Google Scholar]
  8. Coombes RC, Perez D, Gazet JC (1983) Danazol treatment for advanced breast cancer. Cancer Chemother Pharmacol 10:194–195 [DOI] [PubMed] [Google Scholar]
  9. Cooper AP (1836) The principles and practice of surgery. In: Cox (ed) London, vol 1, pp 333–335
  10. Dmowski WP, Headly S, Radawnska E (1983) Effects of danazol on pulsatile gonadotropin patterns and on serum estradiol levels in normally cycling women. Fertil Steril 39:49–55 [DOI] [PubMed] [Google Scholar]
  11. Elridge JC, Dmowski WP, Manesh VB (1974) Effects of castration of immature rats on serum FSH and LH and of various steroid treatments after castration. Biol Reprod 10:438–446 [DOI] [PubMed] [Google Scholar]
  12. EORTC Breast Cancer Cooperative Group (1973) Standards for the assessment of estrogen receptors in human breast cancer. Eur J Cancer 9:379–381 [DOI] [PubMed] [Google Scholar]
  13. Escrich E (1987a) Mammary cancer model induced by dimethylbenz[a]anthracene: a good experimental tool for the study of tumour markers. Int J Biol Markers 2:109–119 [DOI] [PubMed] [Google Scholar]
  14. Escrich E (1987b) Validity of the DMBA-induced mammary cancer model for the study of human breast cancer. Int J Biol Markers 2:197–206 [DOI] [PubMed] [Google Scholar]
  15. Escrich E, Prats M, Ferrer M, Casamitjana R, Gaya JM, Rivera F (1980) Determination of oestrogen receptors in human breast pathology: technical aspects and clinical significance. Pharmatherapeutica 2 [Suppl 2]: 102–107 [Google Scholar]
  16. Horwitz KB, McGuire WL (1975) Specific progesterone receptors in human breast cancer. Steroids 25:497–505 [DOI] [PubMed] [Google Scholar]
  17. Huggins C, Grand LC, Brillantes FP (1961a) Mammary cancer induced by a single feeding of polynuclear hydrocarbons, and its suppression. Nature 189:204–207 [DOI] [PubMed] [Google Scholar]
  18. Huggins C, Morii S, Grant LC (1961b) Mammary cancer induced by a single dose of polynuclear hydrocarbons: routes of administration. Ann Surg 154:315–318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Klijn JCM, Jong FH, Lamberst SWJ, Blankenstein MA (1985) LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23:867–873 [DOI] [PubMed] [Google Scholar]
  20. Kokko E (1983) Progestin-like effects of danazol on rabbit uterus. Endocrinology 112:1110–1114 [DOI] [PubMed] [Google Scholar]
  21. Lineweaver H, Burk D (1934) The determination of enzyme dissociation constants. J Am Chem Soc 56:658–666 [Google Scholar]
  22. Lowry OH, Rosebrough NJ, Farr LA, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275 [PubMed] [Google Scholar]
  23. Manni A, Santen R, Harvey H, Lipton A, Max D (1986) Treatment of breast cancer with gonadotropin-releasing hormone. Endocrine Rev 7:89–94 [DOI] [PubMed] [Google Scholar]
  24. Manson AJ, Stonner FW, Neumann HC, Christiansen RG, Clarke RL, Ackerman JH, Page DF, Dean JW, Philipps DK, Potts GO, Beyler A'L, Clinton RO (1963) Steroidal heterocycles: VII. Androstano (2,3-d)isoxazoles and related compounds. J Med Chem 6:1–9 [DOI] [PubMed] [Google Scholar]
  25. Mathe G, Keiling R, Vovan ML, Gastiaburu J, Prevot G, Vannetzel JM, Despax R, Jasmin C, Levi F, Musset M, Machover D, Misset JL (1986) Phase II trial of D-Trp-6-LH-RH in advanced breast cancer. Abstracts Int Symp Hormonal Manipulation of Cancer, Rotterdam [Google Scholar]
  26. Menon M, Azhar S, Menon KMJ (1980) Evidence that danazol inhibits gonadotropin-induced ovarian steroidogenesis at a point distal to gonadotropin-receptor interaction and adenosine 3′,5′ cyclic monophosphate formation. Am J Obstet Gynecol 136:524–530 [DOI] [PubMed] [Google Scholar]
  27. Musich JR, Behrman SJ, Menon KMJ (1981) Estrogenic and antiestrogenic effects of danazol administration in studies of estraditol receptor binding. J Obstet Gynecol 140:62–69 [DOI] [PubMed] [Google Scholar]
  28. Nicholson RI, Walker KJ, Turkes A, Dyas J, Plowman PN, Williams M, Blamley RW (1965) Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J Steroid Biochem 23:843–847 [DOI] [PubMed] [Google Scholar]
  29. Peters TG, Lewis JD, Wilkinson EJ, Fuhrman TM (1977) Danazol therapy in hormone-sensitive mammary carcinoma. Cancer 40:2797–2800 [DOI] [PubMed] [Google Scholar]
  30. Potts GO, Beyler AL, Schane HP (1974) Pituitary gonadotrophin inhibitory activity of danazol. Fertil Steril 25:367–372 [DOI] [PubMed] [Google Scholar]
  31. Scatchard G (1949) The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 51:660–672 [Google Scholar]
  32. Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA (1985) The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 15:171–173 [DOI] [PubMed] [Google Scholar]
  33. Williams MR, Walker KJ, Turkes A, Blarney RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53:629–636 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wood GP, Wu ChH, Flickinger GL, Mikhail G (1975) Hormonal changes associated with danazol therapy: Obstet Gynecol 45:302–304 [PubMed] [Google Scholar]
  35. Yen SSC (1983) Clinical applications of gonadotropine-releasing hormone and gonadotropin-releasing hormone analogs. Fertil Steril 39:257–266 [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES